Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.74 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.74 |
| ▸ | PDE4A | P27815 | 1/20 | 0.74 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.74 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.74 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SI | P14410 | 1/20 | 0.37 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.37 |
| ▸ | TUBB4A | P04350 | 4/20 | 0.36 |
| ▸ | TUBB | P07437 | 4/20 | 0.36 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.36 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.36 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.36 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.36 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.36 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.36 |
| ▸ | TUBB8 | Q3ZCM7 | 4/20 | 0.36 |
| ▸ | TUBA3E | Q6PEY2 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6858437 | 1.00 | MEN1 (0.74) | MEN1KMT2ACHRM1PDE4APDE4D | |
| SCHEMBL4593681 | 0.97 | MEN1 (0.73) | MEN1KMT2ACHRM1PDE4APDE4D | |
| SCHEMBL4585220 | 0.95 | MEN1 (0.82) | MEN1KMT2ACHRM1PDE4APDE4D | |
| SCHEMBL4586009 | 0.95 | MEN1 (0.82) | MEN1KMT2ACHRM1PDE4APDE4D | |
| SCHEMBL7441633 | 0.95 | MEN1 (0.74) | MEN1KMT2ACHRM1PDE4APDE4D | |
| SCHEMBL3247339 | 0.95 | MEN1 (0.82) | MEN1KMT2ACHRM1PDE4APDE4D | |
| SCHEMBL5426502 | 0.94 | MEN1 (0.84) | MEN1KMT2ACHRM1PDE4APDE4D | |
| SCHEMBL4307435 | 0.94 | MEN1 (0.84) | MEN1KMT2ACHRM1PDE4APDE4D | |
| SCHEMBL3244539 | 0.94 | MEN1 (0.84) | MEN1KMT2ACHRM1PDE4APDE4D | |
| SCHEMBL7440528 | 0.94 | MEN1 (0.69) | MEN1KMT2ACHRM1PDE4APDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032479-A1 | Treatment of inflammatory disorders of the epithelium with low dose 2,3-benzodiazepines | VELA ACQUISITION CORPORATION | 2007-02-08 | — | — | US | claimed |
| US-6864251-B2 | Treatment of LTB4-mediated inflammatory disorders with optically-pure (R)-2,3-benzodiazepines | VELA PHARMACEUTICALS, INC. (US) | 2005-03-08 | — | — | US | claimed |
| US-20040224943-A1 | Method of lowering body temperature with (R) - 2,3-benzodiazepines | VELA ACQUISITION CORPORATION | 2004-11-11 | — | — | US | claimed |
| US-20040138210-A1 | Method of increasing neutrophil production using 2,3-benzodiazepines | VELA PHARMACEUTICALS, INC. | 2004-07-15 | — | — | US | claimed |
| US-20040138209-A1 | Treatment of inflammatory disorders with 2,3- benzodiazepines | VELA PHARMACEUTICALS, INC. | 2004-07-15 | — | — | US | claimed |
| WO-2004050615-A2 | METHOD OF INCREASING NEUTROPHIL PRODUCTION USING 2,3-BENZODIAZEPINES | VELA PHARMACEUTICALS, INC. (US) | 2004-06-17 | — | — | WO | claimed |
| US-20040106602-A1 | Treatment of LTB4-mediated inflammatory disorders with optically-pure (R)-2,3-benzodiazepines | VELA ACQUISITION CORPORATION | 2004-06-03 | — | — | US | claimed |
| US-20040106601-A1 | Method of increasing neutrophil production using optically-pure (R)-2,3-benzodiazepines | VELA ACQUISITION CORPORATION | 2004-06-03 | — | — | US | claimed |
| US-20070032479-A1 | Treatment of inflammatory disorders of the epithelium with low dose 2,3-benzodiazepines | VELA ACQUISITION CORPORATION | 2007-02-08 | — | — | US | disclosed |
| US-7022700-B2 | Method of increasing neutrophil production using optically-pure (R)-2,3-benzodiazepines | VELA PHARMACEUTICALS, INC. (US) | 2006-04-04 | — | — | US | disclosed |
| US-6864251-B2 | Treatment of LTB4-mediated inflammatory disorders with optically-pure (R)-2,3-benzodiazepines | VELA PHARMACEUTICALS, INC. (US) | 2005-03-08 | — | — | US | disclosed |
| US-20040224943-A1 | Method of lowering body temperature with (R) - 2,3-benzodiazepines | VELA ACQUISITION CORPORATION | 2004-11-11 | — | — | US | disclosed |
| US-20040138210-A1 | Method of increasing neutrophil production using 2,3-benzodiazepines | VELA PHARMACEUTICALS, INC. | 2004-07-15 | — | — | US | disclosed |
| US-20040138209-A1 | Treatment of inflammatory disorders with 2,3- benzodiazepines | VELA PHARMACEUTICALS, INC. | 2004-07-15 | — | — | US | disclosed |
| WO-2004050615-A2 | METHOD OF INCREASING NEUTROPHIL PRODUCTION USING 2,3-BENZODIAZEPINES | VELA PHARMACEUTICALS, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
| US-20040106601-A1 | Method of increasing neutrophil production using optically-pure (R)-2,3-benzodiazepines | VELA ACQUISITION CORPORATION | 2004-06-03 | — | — | US | disclosed |
| US-20040106602-A1 | Treatment of LTB4-mediated inflammatory disorders with optically-pure (R)-2,3-benzodiazepines | VELA ACQUISITION CORPORATION | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138209-A1 | Treatment of inflammatory disorders with 2,3- benzodiazepines | LTB4R2, LTB4R, GABRA4 | MEN1 4112/4885KMT2A 2660/4885CHRM1 353/4885 |
| US-20040106602-A1 | Treatment of LTB4-mediated inflammatory disorders with optically-pure (R)-2,3-benzodiazepines | LTB4R2, LTB4R, PTGER4 | MEN1 4227/4885KMT2A 4017/4885CHRM1 359/4885 |
| US-20040106601-A1 | Method of increasing neutrophil production using optically-pure (R)-2,3-benzodiazepines | OPRL1, OPRD1, GABRR1 | MEN1 4420/4885KMT2A 4000/4885CHRM1 131/4885 |
| US-20040224943-A1 | Method of lowering body temperature with (R) - 2,3-benzodiazepines | GABBR1, GABBR2, CYP11B2 | MEN1 2857/4885KMT2A 2115/4885CHRM1 650/4885 |
| US-20070032479-A1 | Treatment of inflammatory disorders of the epithelium with low dose 2,3-benzodiazepines | GABBR2, GABBR1, GABRB3 | MEN1 4138/4885KMT2A 3002/4885CHRM1 60/4885 |
| US-20040138210-A1 | Method of increasing neutrophil production using 2,3-benzodiazepines | GABRR1, GABRA1, GABRA3 | MEN1 4261/4885KMT2A 3420/4885CHRM1 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.